Key facts
- It has raised $39.8M.
- Notable investors include Bpifrance, European Commission, UI Investissement, Elaia Partners, Auriga Partners (Paris) — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Fabentech
- ·The full record, as it builds
Funding rounds
No funding rounds for Fabentech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Fabentech
Developer of immunotherapies and medical technology designed for the treatment of infectious diseases. The company's technology specializes in the composition of highly purified fragments of horse-specific polyclonal immunoglobulins, enabling healthcare institutions to avail themselves of drugs that can address emergency situations effectively.
- Sector
- Healthcare
- HQ
- Lyon, France
- Founded
- 2009
- Employees
- 50
- Website
- fabentech.com/
- Ownership
- Privately Held (backing)
Fabentech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Fabentech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Fabentech in its N-PORT filings yet. We sweep new filings monthly.